On March 31, 2025 Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic," the "Company," or "We"), a leader in RNA-based therapeutics, reported the publication of its latest research paper, titled, "Positive Prognostic Overall Survival Impacts of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients (Press release, Oncotelic, MAR 31, 2025, View Source [SID1234651690])." The paper, authored by Sanjive Qazi, Michael Potts, Scott Myers, Stephen Richardson, and Vuong Trieu, is available online at: View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To facilitate deeper exploration and discussion of this research by the research community, Oncotelic is introducing its proprietary communication platform powered by PDAOAI. PDAOAI enables users to query this paper and dozens of referenced articles through a single interactive interface. Scientists and clinicians are invited to engage at: View Source

A Simple Summary

Glioblastoma (GBM) is one of the most aggressive brain tumors in adults. It is well established that methylation of the O-6-methylguanine-DNA methyltransferase (MGMT) gene is predictive of overall survival (OS) benefits in patients receiving standard temozolomide and radiotherapy. Transforming growth factor beta (TGFB) is a family of cytokines involved in vital cellular processes and the regulation of growth factors.

The study’s novel discovery demonstrates that high TGFB2 gene methylation correlates with an improved OS risk, surpassing the predictive value of MGMT and TGFB1 methylation when controlling for age and sex. Several genes and pathways linked to TGFB2 methylation, including immune mechanisms such as T-cell activation, antigen processing, and Toll-like receptor pathways, were identified as improving survival outcomes in GBM patients. Of note, mucosa-associated lymphoid tissue lymphoma translocation protein, also referred to as MALT1, mRNA negatively impacted survival rates, suggesting a potential avenue for targeted therapies.

"The complexity of the publication was simplified into a concise statement by our PDAOAI platform, demonstrating the power of this platform for scientific communication: The findings underscore the importance of TGFB2 methylation as a prognostic marker in GBM treatment. High levels of TGFB2 methylation are associated with improved overall survival, particularly in young adult males. This suggests that TGFB2 methylation could be a valuable biomarker for risk stratification and therapeutic targeting in GBM, potentially guiding treatment decisions and improving patient outcomes." – Dr. Vuong Trieu, CEO of Oncotelic and co-author of the study.

"Our findings present an actionable opportunity to improve GBM patient outcomes by integrating sophisticated predictive analytical platforms and tools with clinical data. By uncovering insightful methylation patterns and elucidating gene-expression profiles at the biochemical pathway level, we expand our capacity to identify potential therapeutic targets. This approach supports the development of tailored treatment strategies through our nano-technology drug delivery platform. Ultimately, these insights enhance innovation in targeted therapies, driving improved clinical efficacy and patient survival rates in this devastating disease." – Dr. Sanjive Qazi, lead researcher

"This is the first paper we have published that utilized our proprietary AI technology. We are excited to see our technology being applied in real-world scenarios, and we look forward to the advancements it can potentially bring in the future." – Scott Myers, Product Manager